PUBLISHER: The Business Research Company | PRODUCT CODE: 1942753
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942753
A DNA and gene chip is a microchip featuring microscopic DNA probes attached to a solid surface, capable of identifying DNA from test samples and constituting one half of the DNA double helix. When the test sample of DNA carries a mutation, the DNA fails to bind properly to the sequence on the chip. This technology is employed to measure the expression levels of genes or determine whether a person's DNA exhibits mutations, variations in DNA that can lead to diseases.
The main types of DNA and gene chips include oligonucleotide DNA (O-DNA), complementary DNA (C-DNA), and other variations. Oligonucleotide DNA comprises short single- or double-stranded DNA or RNA fragments with three to twenty nucleotides. Products associated with this technology include consumables and instruments, with applications ranging from cancer diagnostics, gene expression, proteomics, genomics, drug discovery, to agrigenomics. End-user industries involved encompass academic and government research institutes, biotechnology and pharmaceutical companies, hospitals and diagnostics centers, among others.
Tariffs are impacting the dna and gene chip market by increasing costs of imported microarray substrates, reagents, scanners, and semiconductor-based fabrication equipment used in chip production. Research institutions and biotechnology companies in North America and Europe are most affected due to dependence on imported precision components, while Asia-Pacific faces higher costs for export-oriented chip manufacturing. These tariffs are increasing procurement expenses and slowing laboratory upgrades. However, they are also encouraging localized manufacturing, domestic reagent production, and regional expansion of genomics fabrication facilities.
The dna and gene chip market research report is one of a series of new reports from The Business Research Company that provides dna and gene chip market statistics, including dna and gene chip industry global market size, regional shares, competitors with a dna and gene chip market share, detailed dna and gene chip market segments, market trends and opportunities, and any further data you may need to thrive in the dna and gene chip industry. This dna and gene chip market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The dna and gene chip market size has grown rapidly in recent years. It will grow from $9.2 billion in 2025 to $10.45 billion in 2026 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to expansion of genomic research activities, increasing adoption of molecular diagnostics, growth of cancer research programs, rising availability of advanced microarray platforms, expansion of academic genomics funding.
The dna and gene chip market size is expected to see rapid growth in the next few years. It will grow to $16.99 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing focus on personalized medicine, rising investments in genomics-based drug discovery, expansion of population-scale genetic screening, growing adoption of ai-driven genomic analytics, increasing use of gene chips in agrigenomics. Major trends in the forecast period include increasing adoption of high-density gene expression arrays, rising use of single-cell analysis chips, growing demand for precision oncology diagnostics, expansion of snp and whole genome analysis chips, enhanced focus on high-throughput genomic screening.
The growing emphasis on early cancer detection is playing a major role in driving the expansion of the DNA and gene chip market. Cancer refers to a wide range of diseases that can originate in almost any organ or tissue when abnormal cells grow uncontrollably, breach normal cellular boundaries, invade surrounding tissues, and spread to other parts of the body. The demand for early detection is increasing as awareness rises about the advantages of identifying cancer at an early stage, encouraging individuals to undergo timely screening that can significantly improve treatment effectiveness and survival rates. DNA and gene chips are widely used to analyze gene expression profiles, assess genetic and epigenetic alterations, and evaluate genomic regulatory elements associated with cancer-related transcription factors in malignant cells. For example, in May 2025, a report published by the National Cancer Institute indicated that the United States is expected to record around 2,041,910 new cancer cases and approximately 618,120 cancer-related deaths in 2025. Similarly, in 2022, data from the American Cancer Society projected nearly 1.9 million newly diagnosed cancer cases and 609,360 deaths in the United States. Consequently, the increasing focus on early cancer detection is supporting the growth of the DNA and gene chip market.
Key players in the DNA and gene chip market are developing innovative genotyping chips, such as the Axiom YNS_Mol1, to advance the food industry and promote insect consumption. The Axiom YNS_Mol1 is a genotyping chip specifically designed for insect breeding, particularly for the Tenebrio Molitor mealworm. For instance, in June 2023, Ynsect, a France-based company specializing in insect production, introduced the world's first genotyping chip for insect breeding, the Axiom YNS_Mol1. Developed in collaboration with Thermo Fisher Scientific, this pioneering chip aims to transform insect breeding for sustainable food and pet food production. It analyzes genetic traits to enhance genomic diversity and improve characteristics such as growth, reproduction, and disease resistance in Tenebrio Molitor mealworms. This innovative initiative is part of Ynsect's YnFABRE project, contributing to the advancement of entomoculture and sustainable solutions in addressing environmental challenges.
In December 2024, Hendrix Genetics, a Netherlands-based animal breeding technology company, entered into a partnership with LABOGENA DNA to obtain exclusive access to high-throughput genotyping services for its multi-species breeding programs. Through this collaboration, Hendrix Genetics seeks to strengthen and accelerate its genotyping capabilities, enabling improved genetic gains across multiple species by leveraging LABOGENA DNA's advanced genotyping infrastructure. LABOGENA DNA, a France-based industrial genotyping and sequencing company, specializes in high-throughput single nucleotide polymorphism (SNP) chip genotyping, targeted sequencing, DNA extraction, custom SNP matrix development, and research and development consulting services, all delivered from its International Organization for Standardization (ISO) 17025-accredited laboratory located near Paris.
Major companies operating in the dna and gene chip market are Illumina Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., CapitalBio Corporation, Microarrays Inc., Applied Microarrays Inc., Biometrix Technology Inc., Oxford Gene Technology IP Limited, Bioneer Corporation, QIAGEN N.V., Bio-Rad Laboratories Inc., BioChain Institute Inc., Fluidigm Corporation, LC Sciences, Macrogen Inc., Greiner Bio-One International GmbH, F. Hoffmann-La Roche Ltd, GE Healthcare, Hitachi High-Technologies Corporation
North America was the largest region in the DNA and gene chip market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dna and gene chip market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the dna and gene chip market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The DNA and gene chip market consists of sales of instrumentation and consumables. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
DNA And Gene Chip Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses dna and gene chip market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for dna and gene chip ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The dna and gene chip market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.